April 2007 TDT signs an exclusive worldwide licensing agreement with DiagnoCure, Inc. of Quebec, Canada. DiagnoCure specializes in the development, production, and commercialization of molecular diagnostics for the detection and management of cancer. The DiagnoCure agreement includes an upfront equity investment, milestone payment, and royalty payments on sales.
May 1994 TDT organized by Harry Arena and three others to take advantage of recent discoveries by Scott A. Waldman, M.D., Ph.D., for both diagnostics and therapeutic applications for colorectal cancer. Technology is based upon Dr. Waldman's 20 years of research in the area of gastrointestinal dysfunction.
June 1994 Discussions initiated with Thomas Jefferson University (TJU), owner of Dr. Waldman's technology.
August 1994

Targeted Diagnostics & Therapeutics, Inc. (TDT) is incorporated in the Commonwealth of Pennsylvania.

TDT and TJU sign a licensing contract giving TDT exclusive worldwide rights to the technology invented by Dr. Waldman in return for annual license fees and royalties on future product sales. Also, TDT agrees to fund Dr. Waldman's laboratory for four years in return for exclusive worldwide rights to all additional intellectual property emanating from that laboratory.
September 1994 Colorectal cancer cells successfully killed in vitro, indicating a potentially powerful cancer therapeutic. However, TDT makes a strategic decision to focus on diagnostic applications, due to the significantly shorter time to bring them to market. TDT's initial objective was to build a strong financial base from which future discoveries and implementations could grow.
October 1994 TDT successfully completes its initial round of seed capital fund raising from private investors.
November 1994 Start of TDT's four-year Research Funding Agreement with TJU. TDT assumes responsibility for ongoing research efforts in Dr. Waldman's laboratory.
December 1994

Organization and initial meeting of TDT's Board of Directors and Scientific Advisory Board.

Dr. Waldman enhances the tissue assay (lymph node) test for in vitro detection of colorectal cancer cells by using molecular diagnostic methods such as polymerase chain reaction ("PCR").
January 1995 Dr. Waldman successfully develops a blood test for in vitro detection of metastatic colorectal cancer cells circulating in patients' blood, using either protein binding or PCR.
May 1996 First US Patent issued - ST receptor binding compounds and methods of using the same.
December 1996 Proceedings of the National Academy of Sciences publishes a research paper showing GCC as a selective marker for colorectal tumors and metastases.
February 1997 U.S. patent issued - Methods of diagnosing colorectal tumors and metastasis thereof.
June 1997 TDT signs Licensing Agreement with Nycomed, Inc. of Oslo, Norway. Nycomed is a leading producer of medical imaging products worldwide. Nycomed agreement includes up-front, maintenance, and milestone payments, plus royalty payments on gross product sales.
July 1997 Nycomed merges with Amersham to create the largest medical imaging company in the world.
March 1998 U.S. patent issued - Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof.
October 1998 U.S. patent issued - Treatment of enterotoxigenic diarrhea with 2- substituted adenosine derivatives.
November 1998 TDT renews its Research Funding Agreement with Thomas Jefferson University.
March 1999 U.S. patent issued - Immuno assay methods for diagnosing colorectal cancer tumors and metastasis thereof.
July 1999 U.S. patent issued - Methods and kits for detection of nucleic acids for diagnosing colorectal cancer tumors and metastasis thereof diagnostic specific for GCC.
October 1999 U.S. patent issued - GCC targeted antisense therapeutics and methods of using same
December 1999 Annals of Internal Medicine publishes findings that show GCC as a biomarker for recurrent Stage II colorectal cancer.
December 1999 Dr. Waldman's technology is featured on CNN news, and story is syndicated to over 50 TV stations throughout the country.
May 2000 U.S. patent issued - In Vivo and In Vitro diagnostics & therapeutics for colorectal cancer and methods of using same.
July 2000 U.S. patent issued - Targeted antisense molecules that bind to colorectal cells and methods using the same
August 2000 TDT moves to 11,000 sq. ft. corporate headquarters in West Chester, Pennsylvania.
September 2000 U.S. patent issued - Methods and kits for detection of nucleic acids in diagnosing colorectal cancer tumors and metastasis thereof.
January 2001 TDT begins construction of research and development laboratories at its West Chester, Pennsylvania location.
February 2001 U.S. patent issued - Methods of identifying and detecting pancreatic cancer.
July 2001

TDT laboratory construction complete. Proceeding of the National Academy of Sciences publishes a research paper showing use of GCC agonists to regulate progression through the cell cycle of human colon carcinoma cells.

U.S. patent issued - Imaging of colorectal cancer using ST Receptor binding compound.
November 2001 TDT signs an exclusive, worldwide licensing Agreement with Millennium Pharmaceuticals, Inc., of Cambridge, MA. Millennium is a leading biopharmaceutical company with a strong oncology franchise in developing breakthrough therapeutic and predictive medical products. The Millennium agreement includes an upfront equity investment, milestone payment and royalty payments on gross sales.
June 2002 The National Cancer Institute of the National Institute of Health awards a $5 million, multi-center grant to The Waldman Labs for clinical trials of GC-C testing. This prospective study will use GC-C testing to monitor patients over a five year period to determine whether cancer has recurred. Results will be compared to conventional histopathology which can miss about 20% of micrometastases.
August 2002 TDT announces a study published in Cancer Epidemiology,
Biomarkers and Prevention which demonstrates the use of GC-C technology as a diagnostic marker for Gastric and Esophageal cancers, broadening the scope of GC-C as a tumor marker.
November 2002 Millennium expands into next research phase for therapy, triggering an additional equity investment.
December 2002 TDT receives Federal certification for commercial testing of GC-C in blood under CLIA ’88 guidelines and by Commonwealth of Pennsylvania.
January 2003 TDT launches blood test for surveillance of recurrent colorectal cancer under the trademark GCC-B1™ Blood Test.